Evaluation of LMR, NLR and PLR as predictors of malignancy in indeterminate thyroid nodules.

indeterminate thyroid nodule lymphocyte-to-monocyte ratio neutrophil-to-lymphocyte ratio platelet-to-lymphocyte ratio thyroid cancer

Journal

Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale
ISSN: 1827-675X
Titre abrégé: Acta Otorhinolaryngol Ital
Pays: Italy
ID NLM: 8213019

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 26 02 2021
accepted: 28 09 2021
entrez: 20 12 2021
pubmed: 21 12 2021
medline: 24 12 2021
Statut: ppublish

Résumé

Thyroid nodules with indeterminate cytology represent 20% of all thyroid nodules. Inflammation plays an important role in cancer. Lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are independent prognostic scores in numerous cancers, although no study has documented their role in cytology indeterminate nodules. The aim of this study is to evaluate the role of LMR, NLR and PLR values as predictors of malignancy in patients with cytology indeterminate nodules. This retrospective study analysed data from 298 patients with indeterminate thyroid nodule. Anatomopathological and haematological data were analysed, dividing the population into two groups. LMR, NLR and PLR values were determined using ROC curve and data were analysed using independent samples t-test, test of proportions, Fisher's exact test and univariate and multivariate logistic regression. We found that a baseline LMR value ≥ 4.09 was indicative of benignity of indeterminate nodule. The probability of malignancy in patients with LMR < 4.09 was 26 times higher than patients with a LMR value ≥ 4.09. This study showed that only LMR has shown a concrete probability to find a thyroid cancer in patients with indeterminate nodules. Further studies are necessary to implement tailored treatment. Valutazione di LMR, NLR e PLR come predittori di malignità in noduli tiroidei indeterminati. I noduli tiroidei a citologia indeterminata rappresentano il 20% di tutti i noduli tiroidei. L’infiammazione gioca un ruolo importante nel cancro. LMR, NLR e PLR sono fattori prognostici indipendenti in numerosi tumori; tuttavia, nessuno studio ha mostrato il loro ruolo nei noduli a citologia indeterminata. Questo studio si propone di valutare il ruolo di LMR, NLR e PLR come predittori di malignità in pazienti con noduli a citologia indeterminata. Abbiamo analizzato retrospettivamente i dati di 298 pazienti con nodulo tiroideo indeterminato. Abbiamo analizzato i dati anatomopatologici ed ematologici, dividendo la popolazione in due gruppi. I valori cut-off di LMR, NLR e PLR sono stati determinati con la curva ROC e i dati sono stati esaminati utilizzando il t-test per campioni indipendenti, il test delle proporzioni, il Fisher exact test e la regressione univariata e multivariata. Un valore LMR basale ≥ 4,09 è indicativo di benignità. La probabilità di neoplasia nei pazienti con LMR < 4,09 è 26 volte superiore rispetto ai pazienti con valore LMR ≥ 4,09. Questo studio ha dimostrato che solo un valore di LMR < 4,09 ha una probabilità concreta che un nodulo a citologia indeterminata possa essere un cancro.

Autres résumés

Type: Publisher (ita)
Valutazione di LMR, NLR e PLR come predittori di malignità in noduli tiroidei indeterminati.

Identifiants

pubmed: 34928264
doi: 10.14639/0392-100X-N1515
pmc: PMC8686799
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

530-536

Informations de copyright

Copyright © 2021 Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale, Rome, Italy.

Références

Diagn Cytopathol. 2010 Oct;38(10):731-9
pubmed: 20049964
BMC Surg. 2019 Apr 24;18(Suppl 1):110
pubmed: 31074400
Cancers (Basel). 2014 Aug 13;6(3):1670-90
pubmed: 25125485
Mol Imaging Radionucl Ther. 2019 Mar 19;28(1):15-20
pubmed: 30942057
Endocr Regul. 2017 Jul 1;51(3):131-136
pubmed: 28858848
Cancer Cytopathol. 2010 Aug 25;118(4):186-9
pubmed: 20586118
Cancer. 2007 Dec 25;111(6):508-16
pubmed: 17999413
Nat Rev Endocrinol. 2016 Nov;12(11):646-653
pubmed: 27418023
J Int Med Res. 2019 May;47(5):2077-2083
pubmed: 30909773
Thyroid. 2019 Jun;29(6):824-829
pubmed: 30864902
Eur J Surg Oncol. 2018 May;44(5):566-570
pubmed: 29530345
Cancer Manag Res. 2019 Sep 17;11:8451-8462
pubmed: 31572000
Endocrine. 2020 Oct;70(1):115-122
pubmed: 32307657
Endocr Metab Immune Disord Drug Targets. 2019;19(6):859-865
pubmed: 30727930
J Gastrointest Cancer. 2019 Sep;50(3):493-506
pubmed: 29704170
Endocr Pract. 2004 Jan-Feb;10(1):31-9
pubmed: 15251619
Cell Immunol. 2017 Jun;316:1-10
pubmed: 28433198
J Endocrinol Invest. 2014 Jun;37(6):593-9
pubmed: 24789536
J Surg Res. 2020 Feb;246:535-543
pubmed: 31711613
Am J Surg. 2013 Jun;205(6):691-6
pubmed: 23388425
Curr Oncol Rep. 2019 Apr 17;21(6):52
pubmed: 30997577
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Lancet. 2016 Dec 3;388(10061):2783-2795
pubmed: 27240885

Auteurs

Chiara Offi (C)

Division of Thyroid Surgery, Department of Medical and Advanced Surgical Sciences, University of Campania "Luigi Vanvitelli", School of Medicine, Naples, Italy.

Roberto Maria Romano (RM)

Division of Thyroid Surgery, Department of Medical and Advanced Surgical Sciences, University of Campania "Luigi Vanvitelli", School of Medicine, Naples, Italy.

Angelo Cangiano (A)

Division of Thyroid Surgery, Department of Medical and Advanced Surgical Sciences, University of Campania "Luigi Vanvitelli", School of Medicine, Naples, Italy.

Marcello Filograna Pignatelli (M)

Division of Thyroid Surgery, Department of Medical and Advanced Surgical Sciences, University of Campania "Luigi Vanvitelli", School of Medicine, Naples, Italy.

Giancarlo Candela (G)

Division of Thyroid Surgery, Department of Medical and Advanced Surgical Sciences, University of Campania "Luigi Vanvitelli", School of Medicine, Naples, Italy.

Giovanni Docimo (G)

Division of Thyroid Surgery, Department of Medical and Advanced Surgical Sciences, University of Campania "Luigi Vanvitelli", School of Medicine, Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH